Headlines about Synlogic (NASDAQ:SYBX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synlogic earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.3741263803443 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
SYBX has been the topic of several recent research reports. Zacks Investment Research downgraded Synlogic from a “hold” rating to a “sell” rating in a research report on Wednesday, May 16th. HC Wainwright initiated coverage on shares of Synlogic in a report on Monday, March 19th. They issued a “buy” rating and a $20.00 price objective for the company. Piper Jaffray Companies reiterated a “buy” rating and set a $15.00 target price on shares of Synlogic in a report on Monday, April 9th. Finally, ValuEngine upgraded shares of Synlogic from a “strong sell” rating to a “sell” rating in a report on Friday, April 27th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $18.20.
Shares of Synlogic traded up $0.03, hitting $9.55, during trading hours on Friday, Marketbeat.com reports. 101,640 shares of the company’s stock traded hands, compared to its average volume of 110,465. Synlogic has a 12-month low of $8.73 and a 12-month high of $23.00. The firm has a market capitalization of $243.05 million, a price-to-earnings ratio of -1.62 and a beta of 1.83.
Synlogic (NASDAQ:SYBX) last released its earnings results on Tuesday, May 15th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.18. The business had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.21 million. analysts forecast that Synlogic will post -2.25 earnings per share for the current year.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.